BofA cuts Smith & Nephew stock price target to $35 on growth concerns

BofA cut its Smith & Nephew (SNN) price target to $35 from $40 while keeping a Buy, lowering its Q2 2026 organic sales model to 3.7% (vs 4.3% consensus) and trimming Knee growth expectations (Q2: -1% vs +1.7% consensus; H2: 3.8% vs 4.8% prior). The firm also reduced fiscal 2026 EPS by 1% and lowered target valuation multiples to 15x P/E and 10x EV/EBITDA from 16.5x and 11x, citing potential Joint Repair softness tied to lower hospital utilization and stricter hospital capital deployment. Separately, Kepler Cheuvreux downgraded SNN from buy to hold, cutting its PT to GBP12.30 from GBP14.62, leaving sentiment cautious into the Aug 4, 2026 Q2 results.

Analysis

This is more a multiple-reset than a thesis break. The market tends to punish medtech names when growth slips from "acceptable" to "good enough," because valuation support comes from the right to compound above GDP; a 1% EPS trim is small, but the signal that near-term knee/joint demand is softer than expected can compress the terminal multiple faster than the earnings cut itself. The immediate risk is not a collapse in fundamentals, but a slower-than-expected re-acceleration that leaves the stock range-bound near the lows for several months.

The bigger second-order issue is competitive: hospital utilization softness and tighter capital deployment usually favor the largest, most diversified orthopedics franchises and the best contract negotiators. If hospital systems are being choosier, SNN is more exposed than peers to mix pressure and delayed product upgrades, while SYK and JNJ can absorb a slower implant cycle with broader procedural exposure. That makes this read-through mildly negative for the orthopedic basket, but not necessarily for the broader medtech group, where names with less knee dependence should look relatively better.

The catalyst path is clear: August 4 earnings will matter less for the quarter itself and more for the next two quarters of knee commentary and any change in FY guide. If management does not show a visible second-half inflection, the de-rating could continue as sell-side models converge lower. The contrarian view is that expectations may already be low enough that stable hospital utilization or better procedure cadence could snap the stock back quickly; the thesis is falsified if organic growth comes in at or above guide and knee returns to positive growth with no further multiple compression.

Key Decisions for Investors

• Relative-value: long SYK / short SNN into the August 4 print, targeting a 1-3 month window where broader elective-procedure resilience should outperform a name with more knee-specific sensitivity.
• If looking for directional exposure, wait for any post-rally bounce in SNN to initiate a tactical short or buy a put spread; reward is a further de-rating toward peer-discounted multiples if growth commentary stays soft, but risk is limited if the stock is already pricing a weak setup.
• Use August 4 as the key catalyst: if SNN guides second-half knee growth above the current conservative street view, cover shorts quickly; if not, expect another leg lower as FY26 EPS and P/E assumptions drift down.
• For a lower-risk expression, own a basket of better-quality medtech names versus SNN rather than shorting the whole group; the divergence should come from procedure mix and pricing power, not a sector-wide demand shock.